Table 3.

Summary of adverse events

AE summary, n (%)	VCD (n = 57)	VCDD (n = 64)
Any AE	47 (82.5)	57 (89.1)
Grade ≥3 AE	23 (40.4)	32 (50.0)
Grade ≥4 AE	4 (7.0)	10 (15.6)
Therapy-related AE	37 (64.9)	47 (73.4)
Grade ≥3 TR-AE	13 (22.8)	21 (32.8)
Grade ≥4 TR-AE	2 (3.5)	8 (12.5)
Daratumumab-related AE		34 (53.1)
Grade ≥3 DR-AE		14 (21.9)
Grade ≥4 DR-AE		6 (9.4)
Drug-related AE leading to permanent discontinuation	4 (7.0)	2 (3.1)
Drug-related AE leading to dose interruption/delay	16 (28.1)	24 (37.5)
Any SAE	14 (24.6)	19 (29.7)
Fatal SAE	0 (0.0)	1 (1.6)
Therapy–related fatal SAE	0 (0.0)	1 (1.6)

AE, adverse event; SAE, serious adverse event.